Opdivo® (nivolumab) and Yervoy® (ipilimumab) – New indication
April 16, 2017 - Bristol-Myers Squibb announced the FDA approval of Opdivo (nivolumab) plus Yervoy (ipilimumab) for the combination treatment of patients with intermediate or poor risk, previously untreated advanced renal cell carcinoma (RCC).
Top